Literature DB >> 33633527

Pain Relief Dependent on IL-17-CD4+ T Cell-β-Endorphin Axis in Rat Model of Brachial Plexus Root Avulsion After Electroacupuncture Therapy.

Zihang Xu1, Yangzhuangzhuang Zhu1, Jun Shen2,3, Lin Su1, Yifei Hou1, Mingxi Liu1, Xiaoning Jiao1, Xiao Chen1, Shiguo Zhu1, Yechen Lu4, Chao Yao1, Lixin Wang1, Chenyuan Gong1, Zhenzhen Ma4, Chunpu Zou1, Jianguang Xu4,5.   

Abstract

BACKGROUND AND
PURPOSE: Neuropathic pain is the typical symptom of brachial plexus root avulsion (BPRA), and no effective therapy is currently available. Electroacupuncture (EA), as a complementary and alternative therapy, plays a critical role in the management of pain-associated diseases. In the present study, we aimed to reveal the peripheral immunological mechanism of EA in relieving the pain of BPRA through the IL-17-CD4+ T lymphocyte-β-endorphin axis.
METHODS: After receiving repeated EA treatment, the pain of BPRA in rats along with the expressions of a range of neurotransmitters, the contents of inflammatory cytokines, and the population of lymphocytes associated were investigated. CD4+ T lymphocytes were either isolated or depleted with anti-CD4 monoclonal antibody. The titers of IL-17A, interferon-γ (IFN-γ), and β-endorphin were examined. The markers of T lymphocytes, myeloid-derived suppressor cells (MDSCs), dendritic cells (DCs), macrophages, and natural killer (NK) cells were assessed. The activation of the nuclear transcription factor κB (NF-κB) signaling pathway was tested.
RESULTS: The pain of BPRA was significantly relieved, and the amount of CD4+ T lymphocytes was increased after EA treatment. The release of β-endorphin was up-regulated with the up-regulation of IL-17A in CD4+ T lymphocytes. The titer of IL-17A was enhanced, leading to an activated NF-κB signaling pathway. The release of β-endorphin and the analgesic effect were almost completely abolished when CD4+ T lymphocytes were depleted.
CONCLUSION: We, for the first time, showed that the neuropathic pain caused by BPRA was effectively relieved by EA treatment via IL-17-CD4+ T lymphocyte-β-endorphin mediated peripheral analgesic effect, providing scientific support for EA clinical application.
Copyright © 2021 Xu, Zhu, Shen, Su, Hou, Liu, Jiao, Chen, Zhu, Lu, Yao, Wang, Gong, Ma, Zou and Xu.

Entities:  

Keywords:  BPRA; CD4+ T lymphocytes; IL-17; neuropathic pain; β-endorphin

Year:  2021        PMID: 33633527      PMCID: PMC7901907          DOI: 10.3389/fnins.2020.596780

Source DB:  PubMed          Journal:  Front Neurosci        ISSN: 1662-453X            Impact factor:   4.677


  38 in total

1.  Neuregulin-1 Accelerates Functional Motor Recovery by Improving Motoneuron Survival After Brachial Plexus Root Avulsion in Mice.

Authors:  Shuangxi Chen; Yuhui Hou; Zhikai Zhao; Yunhao Luo; Shiqin Lv; Qianghua Wang; Jing Li; Liumin He; Libing Zhou; Wutian Wu
Journal:  Neuroscience       Date:  2019-02-05       Impact factor: 3.590

2.  Electro-Acupuncture at Zusanli Acupoint (ST36) Suppresses Inflammation in Allergic Contact Dermatitis Via Triggering Local IL-10 Production and Inhibiting p38 MAPK Activation.

Authors:  Zhigang Wang; Tao Yi; Man Long; Yisen Gao; Chunhao Cao; Chenwei Huang; Qian Wang; Nina Yin; Zebin Chen
Journal:  Inflammation       Date:  2017-08       Impact factor: 4.092

Review 3.  Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies.

Authors:  José María G Ruiz de Morales; Lluís Puig; Esteban Daudén; Juan D Cañete; José Luis Pablos; Antonio Olveira Martín; Carlos González Juanatey; Alfredo Adán; Xavier Montalbán; Natalia Borruel; Guillermo Ortí; Esther Holgado-Martín; Carolina García-Vidal; Cynthia Vizcaya-Morales; Víctor Martín-Vázquez; Miguel Ángel González-Gay
Journal:  Autoimmun Rev       Date:  2019-11-15       Impact factor: 9.754

Review 4.  Acupuncture and Chronic Pain Management.

Authors:  Ladan Eshkevari
Journal:  Annu Rev Nurs Res       Date:  2017-01

5.  Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes.

Authors:  Patrick A Hughes; Andrea M Harrington; Joel Castro; Tobias Liebregts; Birgit Adam; Dallas J Grasby; Nicole J Isaacs; Lochana Maldeniya; Chris M Martin; Jenny Persson; Jane M Andrews; Gerald Holtmann; L Ashley Blackshaw; Stuart M Brierley
Journal:  Gut       Date:  2012-07-05       Impact factor: 23.059

6.  Spinal DN-9, a Peptidic Multifunctional Opioid/Neuropeptide FF Agonist Produced Potent Nontolerance Forming Analgesia With Limited Side Effects.

Authors:  Zilong Wang; Biao Xu; Changyu Jiang; Ting Zhang; Mengna Zhang; Ning Li; Qinqin Zhang; Kangtai Xu; Dan Chen; Jian Xiao; Quan Fang
Journal:  J Pain       Date:  2019-09-12       Impact factor: 5.820

7.  Decreased expression of lncRNA Malat1 in rat spinal cord contributes to neuropathic pain by increasing neuron excitability after brachial plexus avulsion.

Authors:  Chong Meng; Xun Yang; Yuzhou Liu; Yingjie Zhou; Jing Rui; Shenqian Li; Ce Xu; Yongqing Zhuang; Jie Lao; Xin Zhao
Journal:  J Pain Res       Date:  2019-04-23       Impact factor: 3.133

8.  Electroacupuncture Alleviates Paclitaxel-Induced Peripheral Neuropathic Pain in Rats via Suppressing TLR4 Signaling and TRPV1 Upregulation in Sensory Neurons.

Authors:  Yuanyuan Li; Chengyu Yin; Xiaojie Li; Boyu Liu; Jie Wang; Xiaoli Zheng; Xiaomei Shao; Yi Liang; Junying Du; Jianqiao Fang; Boyi Liu
Journal:  Int J Mol Sci       Date:  2019-11-25       Impact factor: 5.923

Review 9.  The Role of NF-κB in Physiological Bone Development and Inflammatory Bone Diseases: Is NF-κB Inhibition "Killing Two Birds with One Stone"?

Authors:  Eijiro Jimi; Nana Takakura; Fumitaka Hiura; Ichiro Nakamura; Shizu Hirata-Tsuchiya
Journal:  Cells       Date:  2019-12-14       Impact factor: 6.600

10.  Modulation of anti-tumor immunity by the brain's reward system.

Authors:  Tamar L Ben-Shaanan; Maya Schiller; Hilla Azulay-Debby; Ben Korin; Nadia Boshnak; Tamar Koren; Maria Krot; Jivan Shakya; Michal A Rahat; Fahed Hakim; Asya Rolls
Journal:  Nat Commun       Date:  2018-07-13       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.